Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

(1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of activating another p53 family member, p73, which has not been well studie...

Full description

Bibliographic Details
Main Authors: Pierre-Samuel Gillardin, Géraldine Descamps, Sophie Maiga, Benoit Tessoulin, Hanane Djamai, Benedetta Lucani, David Chiron, Philippe Moreau, Steven Le Gouill, Martine Amiot, Catherine Pellat-Deceunynck, Agnès Moreau-Aubry
Format: Article
Language:English
Published: MDPI AG 2017-12-01
Series:International Journal of Molecular Sciences
Subjects:
multiple myeloma
p53
p73
CpG methylation
decitabine
alkylating drugs
Online Access:https://www.mdpi.com/1422-0067/19/1/40

Internet

https://www.mdpi.com/1422-0067/19/1/40

Similar Items